|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0650 - 0.9900|
|52 Week Range||0.0650 - 0.9900|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) ("MindMed'' or the "Company") announces that it has completed its previously announced redesignation of its subordinate voting shares as common shares (the "Common Shares") of the Company. The Common Shares will be assigned CUSIP number 60255C802 and ISIN number CA60255C8025 following the redesignation. The Common Shares will begin trading on a post-Redesignation basis under the new CUSIP and ISIN numbers on the NEO Exchange and NASDAQ at m
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's annual general and special meeting of shareholders held on June 1, 2022 (the "Meeting").
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Robert Barrow, Chief Executive Officer and Director, will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY from June 8-10, 2022.